Amy B Heimberger

List of Publications by Year
in descending order

162
papers

16,036
citations

20797

60
h-index

18115

120
g-index

170
all docs

170
docs citations

170
times ranked

15991
citing authors

#	Article	IF	Citations
1	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	3.2	18
2	New Approaches to Glioblastoma. Annual Review of Medicine, 2022, 73, 279-292.	5.0	14
3	Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight, 2022, 7, .	2.3	7
4	Next-Generation Sequencing of a Glioblastoma with True Epithelial Differentiation. Journal of Neuropathology and Experimental Neurology, 2022, 81, 239-241.	0.9	1
5	Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunology Research, 2022, 10, 770-784.	1.6	34
6	B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. Molecular Cancer Therapeutics, 2022, 21, 999-1009.	1.9	8
7	Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. OncoImmunology, 2022, 11, 2062827.	2.1	6
8	Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. Cancer Cell, 2022, 40, 439-440.	7.7	27
9	A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 139-146.	1.8	1
10	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology, 2022, 11, CNS87.	1.2	15
11	Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends in Cancer, 2022, 8, 839-854.	3.8	23
12	Abstract 2548: The central nervous system immune cell interactome is a function of cancer lineage, tumor microenvironment and STAT3 expression. Cancer Research, 2022, 82, 2548-2548.	0.4	0
13	Immune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight, 2022, 7, .	2.3	10
14	Bloodâ€“brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. Journal of Neuro-Oncology, 2021, 151, 65-73.	1.4	31
15	What is the burden of proof for tumor mutational burden in gliomas?. Neuro-Oncology, 2021, 23, 17-22.	0.6	15
16	The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers, 2021, 13, 437.	1.7	59
17	Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Science Advances, 2021, 7, .	4.7	54
18	Context-Dependent Glioblastomaâ€“Macrophage/Microglia Symbiosis and Associated Mechanisms. Trends in Immunology, 2021, 42, 280-292.	2.9	42

#	Article	IF	Citations
19	FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. Cancer Letters, 2021, 506, 83-94.	3.2	25
20	Opening of the Bloodâ€"Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clinical Cancer Research, 2021, 27, 4325-4337.	3.2	58
21	The immune landscape of common CNS malignancies: implications for immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 729-744.	12.5	50
22	Phase II Trial of Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival between RANO vs. Clinical Assessment. Neuro-Oncology Advances, 2021, 3, vdab073.	0.4	1
23	Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. BMC Neurology, 2021, 21, 231.	0.8	9
24	Targeting the Î±v integrin/TGF-Î² axis improves natural killer cell function against glioblastoma stem cells. Journal of Clinical Investigation, 2021, 131, .	3.9	117
25	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
26	Circadian regulation of cancer cell and tumor microenvironment crosstalk. Trends in Cell Biology, 2021, 31, 940-950.	3.6	42
27	Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clinical Cancer Research, 2021, 27, 5528-5535.	3.2	22
28	Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. Frontiers in Oncology, 2021, 11, 682129.	1.3	2
29	Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. Cells, 2021, 10, 2032.	1.8	12
30	LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease. Neuro-Oncology Advances, 2021, 3, iii11-iii12.	0.4	0
31	Qki is an essential regulator of microglial phagocytosis in demyelination. Journal of Experimental Medicine, 2021, 218, .	4.2	13
32	Unique challenges for glioblastoma immunotherapyâ€"discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	0.6	59
33	CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Frontiers in Immunology, 2021, 12, 745893.	2.2	6
34	American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors. Future Oncology, 2021, 17, 4425-4429.	1.1	0
35	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Science Translational Medicine, 2021, 13, eabe6201.	5.8	19
36	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2021, 2, 1372-1386.	5.7	39

#	Article	IF	Citations
37	The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. International Journal of Molecular Sciences, 2021, 22, 13382.	1.8	14
38	Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications. Neuro-Oncology, 2020, 22, 180-194.	0.6	95
39	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine, 2020, 26, 39-46.	15.2	236
40	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology, 2020, 22, 539-549.	0.6	98
41	MiR-181 Family Modulates Osteopontin in Glioblastoma Multiforme. Cancers, 2020, 12, 3813.	1.7	12
42	CD8+ T-cellâ€"Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clinical Cancer Research, 2020, 26, 4390-4401.	3.2	36
43	Antiâ€"PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clinical Cancer Research, 2020, 26, 4699-4712.	3.2	65
44	Radiation with STAT3 Blockade Triggers Dendritic Cellâ€"T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clinical Cancer Research, 2020, 26, 4983-4994.	3.2	38
45	Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell, 2020, 37, 243-257.e7.	7.7	59
46	Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients?. Neuro-Oncology, 2020, 22, 590-591.	0.6	0
47	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clinical Cancer Research, 2020, 26, 3565-3577.	3.2	30
48	IMMU-35. TRANSCRIPTIONALLY DEFINED IMMUNE CONTEXTURE IN HUMAN GLIOMAS AT SINGLE-CELL RESOLUTION. Neuro-Oncology, 2020, 22, ii112-ii112.	0.6	2
49	Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight, 2020, 5, .	2.3	43
50	Mature myelin maintenance requires Qki to coactivate PPARÎ²-RXRÎ±â€"mediated lipid metabolism. Journal of Clinical Investigation, 2020, 130, 2220-2236.	3.9	50
51	Microglia promote glioblastoma via mTORâ€mediated immunosuppression of the tumour microenvironment. EMBO Journal, 2020, 39, e103790.	3.5	77
52	The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. Journal of the National Cancer Institute, 2019, 111, 292-300.	3.0	32
53	Immune checkpoint blockade in glioma. , 2019, , 387-396.		0
54	Immunomodulatory Methods. , 2019, , 297-334.		2

#	Article	IF	Citations
55	Shortened ex vivo manufacturing time of EGFRvIII-specific chimeric antigen receptor (CAR) T cells reduces immune exhaustion and enhances antiglioma therapeutic function. Journal of Neuro-Oncology, 2019, 145, 429-439.	1.4	33
56	FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nature Communications, 2019, 10, 448.	5.8	65
57	Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment. Expert Opinion on Therapeutic Targets, 2019, 23, 647-649.	1.5	3
58	TMIC-60. COMPREHENSIVE SPATIAL CHARACTERIZATION OF IMMUNE CELLS IN THE CNS BRAIN TUMOR MICROENVIRONMENT. Neuro-Oncology, 2019, 21, vi261-vi261.	0.6	4
59	Identification of metabolites in plasma for predicting survival in glioblastoma. Molecular Carcinogenesis, 2018, 57, 1078-1084.	1.3	28
60	Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. Nature Communications, 2018, 9, 1219.	5.8	20
61	Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. Journal of Neuro-Oncology, 2018, 136, 33-39.	1.4	4
62	Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. OncoImmunology, 2018, 7, e1412909.	2.1	247
63	Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. Journal of Neuro-Oncology, 2018, 139, 469-478.	1.4	18
64	Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Letters, 2018, 433, 176-185.	3.2	28
65	Rethinking medulloblastoma from a targeted therapeutics perspective. Journal of Neuro-Oncology, 2018, 139, 713-720.	1.4	17
66	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	2.3	31
67	Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. Journal of Clinical Investigation, 2018, 129, 137-149.	3.9	242
68	Immune Checkpoint Inhibitors for Brain Metastases. Current Oncology Reports, 2017, 19, 38.	1.8	18
69	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro-Oncology, 2017, 19, 1047-1057.	0.6	325
70	Tumor Vaccines for Malignant Gliomas. Neurotherapeutics, 2017, 14, 345-357.	2.1	41
71	Serum microRNA profiling in patients with glioblastoma: a survival analysis. Molecular Cancer, 2017, 16, 59.	7.9	55
72	Immune Checkpoint Inhibitors in Gliomas. Current Oncology Reports, 2017, 19, 23.	1.8	27

#	Article	IF	Citations
73	Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell, 2017, 32, 42-56.e6.	7.7	1,282
74	Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nature Genetics, 2017, 49, 75-86.	9.4	74
75	Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget, 2017, 8, 101244-101254.	0.8	25
76	Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight, 2016, 1, .	2.3	356
77	Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. Journal of Immunotherapy, 2016, 39, 205-217.	1.2	29
78	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro-Oncology, 2016, 18, 1357-1366.	0.6	116
79	Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. OncoImmunology, 2016, 5, e1117739.	2.1	7
80	Interrogating Metabolism in Brain Cancer. Magnetic Resonance Imaging Clinics of North America, 2016, 24, 687-703.	0.6	17
81	Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro-Oncology, 2016, 19, now198.	0.6	23
82	Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncology, 2016, 5, 175-186.	1.2	11
83	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology, 2016, 18, 639-648.	0.6	161
84	Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?. Immunotherapy, 2016, 8, 413-423.	1.0	7
85	Principles of immunotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 163-181.	1.0	12
86	Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 2016, 5, e1145332.	2.1	13
87	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	0.6	463
88	Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells. Oncotarget, 2016, 7, 72021-72032.	0.8	44
89	Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget, 2016, 7, 20486-20495.	0.8	49
90	Signal transducer and activator of transcription 5b drives malignant progression in a <scp>PDGFB</scp>â€dependent proneural glioma model by suppressing apoptosis. International Journal of Cancer, 2015, 136, 2047-2054.	2.3	11

#	Article	IF	Citations
91	IMPS-28PD-L1 EXPRESSION AND PROGNOSTIC IMPACT IN GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v119.2-v119.	0.6	3
92	A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro-Oncology, 2015, 17, 854-861.	0.6	335
93	The role of STAT3 in tumor-mediated immune suppression. Journal of Neuro-Oncology, 2015, 123, 385-394.	1.4	55
94	FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. Journal of the National Cancer Institute, 2015, 107, .	3.0	80
95	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. Neuro-Oncology, 2015, 17, vii9-vii14.	0.6	275
96	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Research, 2015, 75, 3505-3518.	0.4	327
97	The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. International Reviews of Immunology, 2014, 35, 1-15.	1.5	41
98	Therapeutic targets in subependymoma. Journal of Neuroimmunology, 2014, 277, 168-175.	1.1	21
99	Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege. Clinical Cancer Research, 2014, 20, 5620-5629.	3.2	91
100	Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro-Oncology, 2014, 16, viii20-viii25.	0.6	29
101	Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine Glioblastoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	112
102	Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy. Cancer Immunology Research, 2014, 2, 867-877.	1.6	79
103	miR-124 Inhibits STAT3 Signaling to Enhance T Cellâ€"Mediated Immune Clearance of Glioma. Cancer Research, 2013, 73, 3913-3926.	0.4	223
104	Mesenchymal Differentiation Mediated by NF-Îº B Promotes Radiation Resistance in Glioblastoma. Cancer Cell, 2013, 24, 331-346.	7.7	856
105	MicroRNAs as novel immunotherapeutics. OncoImmunology, 2013, 2, e25124.	2.1	4
106	Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas. Cancer Immunology Research, 2013, 1, 112-122.	1.6	192
107	The Controversial Role of Microglia in Malignant Gliomas. Clinical and Developmental Immunology, 2013, 2013, 1-12.	3.3	166
108	Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro-Oncology, 2012, 14, 1136-1145.	0.6	73

#	Article	IF	Citations
109	Consensus on the role of human cytomegalovirus in glioblastoma. Neuro-Oncology, 2012, 14, 246-255.	0.6	245
110	Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma. Oncotarget, 2012, 3, 1036-1048.	0.8	71
111	The tumor microenvironment expression of pâ€STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. International Journal of Cancer, 2012, 131, 8-17.	2.3	36
112	miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma. Clinical Investigation, 2011, 1, 1637-1650.	0.0	8
113	Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?. Neuro-Oncology, 2011, 13, 3-13.	0.6	97
114	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology, 2011, 13, 324-333.	0.6	306
115	Reply to M.C. Chamberlain. Journal of Clinical Oncology, 2011, 29, e519-e520.	0.8	1
116	Reply to M.S. Lesniak. Journal of Clinical Oncology, 2011, 29, 3105-3106.	0.8	9
117	Brain Tumor Immunology and Immunotherapy. , 2011, , 1087-1101.		1
118	Hypoxia Potentiates Glioma-Mediated Immunosuppression. PLoS ONE, 2011, 6, e16195.	1.1	177
119	The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies. , 2011, 2, 163.		10
120	Immune therapeutic targeting of glioma cancer stem cells. Targeted Oncology, 2010, 5, 217-227.	1.7	31
121	Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses. Clinical Cancer Research, 2010, 16, 5722-5733.	3.2	71
122	Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression. Clinical Cancer Research, 2010, 16, 461-473.	3.2	212
123	Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. Molecular Cancer Therapeutics, 2010, 9, 67-78.	1.9	253
124	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 2010, 28, 4722-4729.	0.8	702
125	Inhibition of p-STAT3 Enhances IFN-Î± Efficacy against Metastatic Melanoma in a Murine Model. Clinical Cancer Research, 2010, 16, 2550-2561.	3.2	51
126	The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention. Neurosurgery Clinics of North America, 2010, 21, 125-137.	0.8	67

#	Article	IF	Citations
127	Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. Neurosurgery Clinics of North America, 2010, 21, 95-109.	0.8	21
128	Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncology, 2010, 12, 1113-1125.	0.6	530
129	Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia. PLoS ONE, 2009, 4, e5947.	1.1	95
130	An epidermal growth factor receptor variant IIIâ€"targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics, 2009, 8, 2773-2779.	1.9	262
131	The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opinion on Biological Therapy, 2009, 9, 1087-1098.	1.4	79
132	IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the Temozolomide era. International Journal of Cancer, 2009, 125, 680-687.	2.3	73
133	Topotecan enhances immune clearance of gliomas. Cancer Immunology, Immunotherapy, 2009, 58, 259-270.	2.0	18
134	A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunology, Immunotherapy, 2009, 58, 1023-1032.	2.0	74
135	EGFRvIIIâ€Targeted Vaccination Therapy of Malignant Glioma. Brain Pathology, 2009, 19, 713-723.	2.1	118
136	yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. Journal of Translational Medicine, 2009, 7, 92.	1.8	7
137	Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 123-131.	2.0	210
138	Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Journal of Immunological Methods, 2008, 339, 74-81.	0.6	48
139	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Seminars in Immunology, 2008, 20, 267-275.	2.7	156
140	The Incidence, Correlation with Tumor-Infiltrating Inflammation, and Prognosis of Phosphorylated STAT3 Expression in Human Gliomas. Clinical Cancer Research, 2008, 14, 8228-8235.	3.2	174
141	Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro-Oncology, 2008, 10, 98-103.	0.6	109
142	A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells. Clinical Cancer Research, 2008, 14, 5759-5768.	3.2	111
143	Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas. Clinical Cancer Research, 2008, 14, 5166-5172.	3.2	280
144	Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma. Journal of Clinical Oncology, 2007, 25, 2288-2294.	0.8	260

#	Article	IF	Citations
145	Cytochrome P450 1B1 Expression in Glial Cell Tumors: An Immunotherapeutic Target. Clinical Cancer Research, 2007, 13, 3559-3567.	3.2	32
146	A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients. Cancer Research, 2007, 67, 9630-9636.	0.4	278
147	Innovative Treatment Strategies for High-Grade Gliomas. , 2007, , 171-190.		0
148	Innate immune functions of microglia isolated from human glioma patients. Journal of Translational Medicine, 2006, 4, 15.	1.8	91
149	The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1. Neuro-Oncology, 2006, 8, 261-279.	0.6	516
150	The Role of Glioma Microenvironment in Immune Modulation: Potential Targets for Intervention. Letters in Drug Design and Discovery, 2006, 3, 443-453.	0.4	11
151	Mechanisms of action of rapamycin in gliomas. Neuro-Oncology, 2005, 7, 1-11.	0.6	27
152	Immunotherapy for human glioma: innovative approaches and recent results. Expert Review of Anticancer Therapy, 2005, 5, 777-790.	1.1	37
153	Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. Clinical Cancer Research, 2005, 11, 1462-1466.	3.2	446
154	The natural history of EGFR and EGFRvIII in glioblastoma patients. Journal of Translational Medicine, 2005, 3, 38.	1.8	180
155	Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clinical Cancer Research, 2005, 11, 267-72.	3.2	38
156	Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clinical Cancer Research, 2003, 9, 4247-54.	3.2	175
157	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. Neurosurgery, 2002, 50, 158-166.	0.6	81
158	Dendritic Cells Pulsed with a Tumor-specific Peptide Induce Long-lasting Immunity and Are Effective against Murine Intracerebral Melanoma. Neurosurgery, 2002, 50, 158-166.	0.6	66
159	Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clinical Cancer Research, 2002, 8, 3496-502.	3.2	138
160	Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. Journal of Neuroimmunology, 2000, 103, 16-25.	1.1	128
161	Biological Principles of Brain Tumor Immunotherapy. , 0, , 101-130.		5
162	Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era. Frontiers in Immunology, 0, 13, .	2.2	4